BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 18538015)

  • 21. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.
    Hebert C; Norris K; Parashar P; Ord RA; Nikitakis NG; Sauk JJ
    Mol Cancer; 2006 Jan; 5():3. PubMed ID: 16412252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN expression and methylation status in oral squamous cell carcinoma.
    Kurasawa Y; Shiiba M; Nakamura M; Fushimi K; Ishigami T; Bukawa H; Yokoe H; Uzawa K; Tanzawa H
    Oncol Rep; 2008 Jun; 19(6):1429-34. PubMed ID: 18497947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma.
    Lee CH; Wong TS; Chan JY; Lu SC; Lin P; Cheng AJ; Chen YJ; Chang JS; Hsiao SH; Leu YW; Li CI; Hsiao JR; Chang JY
    J Pathol; 2013 Jul; 230(3):298-309. PubMed ID: 23362108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.
    Niida Y; Stemmer-Rachamimov AO; Logrip M; Tapon D; Perez R; Kwiatkowski DJ; Sims K; MacCollin M; Louis DN; Ramesh V
    Am J Hum Genet; 2001 Sep; 69(3):493-503. PubMed ID: 11468687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.
    Bhatia V; Goel MM; Makker A; Tewari S; Yadu A; Shilpi P; Kumar S; Agarwal SP; Goel SK
    Biomed Res Int; 2014; 2014():248419. PubMed ID: 24991542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma.
    Lai YH; He RY; Chou JL; Chan MW; Li YF; Tai CK
    J Transl Med; 2014 Sep; 12():237. PubMed ID: 25179542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
    Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
    Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation.
    Lee CH; Pan KL; Tang YC; Tsai MH; Cheng AJ; Shen MY; Cheng YM; Huang TT; Lin P
    Oncotarget; 2015 Sep; 6(28):25188-201. PubMed ID: 26317789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
    Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
    PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Fan QY; Haughey M; Samsel L; El-Chemaly S; Wu HP; McCoy JP; Steagall WK; Lin JP; Darling TN; Moss J
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1410-8. PubMed ID: 20639436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.
    Lesma E; Sirchia SM; Ancona S; Carelli S; Bosari S; Ghelma F; Montanari E; Di Giulio AM; Gorio A
    Am J Pathol; 2009 Jun; 174(6):2150-9. PubMed ID: 19443708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
    J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
    Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
    Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients.
    Supić G; Kozomara R; Branković-Magić M; Jović N; Magić Z
    Oral Oncol; 2009 Dec; 45(12):1051-7. PubMed ID: 19665921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
    Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
    Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma.
    Ishida E; Nakamura M; Ikuta M; Shimada K; Matsuyoshi S; Kirita T; Konishi N
    Oral Oncol; 2005 Jul; 41(6):614-22. PubMed ID: 15975525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of p300 in the tumor progression of oral squamous cell carcinoma.
    Cho YA; Hong JS; Choe EJ; Yoon HJ; Hong SD; Lee JI; Hong SP
    J Oral Pathol Med; 2015 Mar; 44(3):185-92. PubMed ID: 25154636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated methylation and gene expression microarray analysis reveals significant prognostic biomarkers in oral squamous cell carcinoma.
    Zhao C; Zou H; Zhang J; Wang J; Liu H
    Oncol Rep; 2018 Nov; 40(5):2637-2647. PubMed ID: 30226546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.